There has been no company like Amazon.com (Nasdaq: AMZN) ever with the ability to affect entire industries just by announcing its entry. The most recent example of this was in late June when Amazon announced a roughly $1 billion acquisition of PillPack, a mail-order pharmacy that packages pills into daily portions before shipping them to […]
In the midst of a much-needed turnaround and upcoming name change, one very well-known pharmaceutical company just suffered a setback on a new drug. And with an astonishing level of debt, investors might have got too carried away with the story. A simple name change won’t fix this stock.
And investors’ No. 1 worry going into 2018 is… Geopolitical risks. In a poll on MarketWatch’s Twitter site last week, such concerns narrowly edged out the possibility of a bitcoin crash as the top reason for investor angst. If you listen to market experts, though, they’re more concerned with the current bull market hitting the […]
A recent approval from an U.S. Food and Drug Administration (FDA) advisory panel has heralded a new era of medicine. An era where diseases are tackled in a totally different way, by inserting into disease sufferers functioning copies of genes that are either missing or mutated. Gene therapy is a complex subject. So think of […]
Remember the days when political strife and geopolitical volatility used to spook investors and send tremors through the stock market? I do… but those memories are fading fast. Given the current climate, you’d think the phrase “market jitters” would appear more often. After all, if there’s one thing the market hates, it’s uncertainty. Yet stocks […]
Imagine a world where a person’s cells are “re-engineered” to recognize and attack cancer, so that conventional therapies are not needed. Science fiction, right? Thankfully, no! It’s all part of the move toward personalized medicine. Welcome to the world of chimeric antigen receptor cell therapy or Car-T, which has given hope to thousands of blood […]
Climbing almost 10% in one week alone, it looks like the biotech sector is back in business. If you’re looking to gain some exposure to the rally but don’t want to invest in small, risky pot-shots, take a look at these two stocks. They’re the only two that Growth Stock Advisor Tony Daltorio would buy […]